Complement Inhibitor Therapy for Myasthenia Gravis
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2020.00917
Abstract: Complement activation as a driver of pathology in myasthenia gravis (MG) has been appreciated for decades. The terminal complement component [membrane attack complex (MAC)] is found at the neuromuscular junctions of patients with MG. Animals… read more here.
Keywords: complement inhibitor; inhibitor therapy; therapy myasthenia; complement ... See more keywords